Clinical trial
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
NCT00093964 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00093964 |
|---|---|
| Title | Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) |
| Official title | A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent. |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Cilengitide 500 mg, Cilengitide 2000 mg |
| Enrollment | 81 |
| Start date | Oct 13, 2004 |
| Primary completion | Oct 28, 2005 |
| Completion | Oct 21, 2010 |
| First posted | Oct 11, 2004 |
| Last update posted | Apr 16, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: